Jeremy Shinoda

Publications
ResearchGate - Google Scholar - ORCID - SSRN - Scopus

Cancer Gene Therapy, 13, 169–181. doi:10.1038/sj.cgt.7700870
Biological Activities of a Recombinant Adenovirus p53 (SCH 58500) Administered by Hepatic Arterial Infusion in a Phase I Colorectal Cancer Trial
Cancer Gene Therapy, 10, 224–238. doi:10.1038/sj.cgt.7700562
Assessment of p53 Gene Transfer and Biological Activities in a Clinical Study of Adenovirus-p53 Gene Therapy for Recurrent Ovarian Cancer
BioTechniques Preclinica, 1(4): 187-197
Variations in Backbone and Promoters in Recombinant Adenoviruses Expressing Human p21WAF1/Cip1 for Potential Use in Ocular Gene Therapy
JAMA Opthalmology/Archives of Ophthalmology;120(7):941-949. doi:10.1001/archopht.120.7.941.
Adenovirus-Mediated Gene Therapy Using Human p21WAF-1/Cip-1 to Prevent Wound Healing in a Rabbit Model of Glaucoma Filtration Surgery
Molecular Therapy, 3, 768–778; doi: 10.1006/mthe.2001.0316
Specific Depletion of Human Anti-Adenovirus Antibodies Facilitates Transduction in an In Vivo Model for Systemic Gene Therapy
The Journal of Immunology, 167(2) 1053-1059. doi: 10.4049/jimmunol.167.2.1053
Adenoviral Delivery of Human and Viral IL-10 in Murine Sepsis
Cancer Gene Therapy, 8, 788-795
Interferon Alpha2b Gene Delivery Using Adenoviral Vector Causes Inhibition of Tumor Growth in Xenograft Models from a Variety of Cancers
Proceedings of the American Society of Clinical Oncology, 20, A849
Evidence of p53 Gene Transfer and its Biological Activities in Ovarian Cancer Patients Receiving Multiple Cycles of Recombinant Adenovirus Expressing Wild-Type p53
Cancer Gene Therapy, 7, S7-S8.
Analysis of Serial Biopsies and Ascites from a Phase I Trial of Adenovirus-Mediated p53 Gene Therapy in Recurrent Ovarian Cancer

Jeremy Shinoda

Science - Data - Regulatory Compliance - Marketing - Food - Travel - Local - Bicycle - Design - Civic Engagement - Español - 李锦源 - MBA, BS, BA

Publications

ResearchGate - Google Scholar - ORCID - SSRN - Scopus

Cancer Gene Therapy, 13, 169–181. doi:10.1038/sj.cgt.7700870

Cancer Gene Therapy, 10, 224–238. doi:10.1038/sj.cgt.7700562

BioTechniques Preclinica, 1(4): 187-197

JAMA Opthalmology/Archives of Ophthalmology;120(7):941-949. doi:10.1001/archopht.120.7.941.

Molecular Therapy, 3, 768–778; doi: 10.1006/mthe.2001.0316

The Journal of Immunology, 167(2) 1053-1059. doi: 10.4049/jimmunol.167.2.1053

Cancer Gene Therapy, 8, 788-795

Proceedings of the American Society of Clinical Oncology, 20, A849

Cancer Gene Therapy, 7, S7-S8.

Jeremy Shinoda

Science - Data - Regulatory Compliance - Marketing - Food - Travel - Local - Bicycle - Design - Civic Engagement - Español - 李锦源 - MBA, BS, BA

Publications

ResearchGate - Google Scholar - ORCID - SSRN - Scopus

Cancer Gene Therapy, 13, 169–181. doi:10.1038/sj.cgt.7700870

Cancer Gene Therapy, 10, 224–238. doi:10.1038/sj.cgt.7700562

BioTechniques Preclinica, 1(4): 187-197

JAMA Opthalmology/Archives of Ophthalmology;120(7):941-949. doi:10.1001/archopht.120.7.941.

Molecular Therapy, 3, 768–778; doi: 10.1006/mthe.2001.0316

The Journal of Immunology, 167(2) 1053-1059. doi: 10.4049/​jimmunol.167.2.1053

Cancer Gene Therapy, 8, 788-795

Proceedings of the American Society of Clinical Oncology, 20, A849

Cancer Gene Therapy, 7, S7-S8.

The Journal of Immunology, 167(2) 1053-1059. doi: 10.4049/jimmunol.167.2.1053